Session: FP34-Molecular Mechanisms in Thyroid Hormone Action & Cancer
Room 103 (Moscone Center)
Poster Board MON-415
An increase in serum TT3 concentration levels was observed, significant after 1 hour, further increased at 2 and 4 hours, and then remained steady up to 48 hours after T3S administration. In the 160 mcg group, the mean serum TT3 increase (ng/dl, minus baseline) was: 10.5 (1 h), 17.7 (2 h), 23.6 (4 h), 17.7 (8 h), 19.7 (12 h), 28.2 (24 h), 22.7 (48 h). There was a significant direct correlation between the TT3 AUC 0-48h and the administered dose of T3S. No changes in serum free thyroxine concentrations during the entire study period were observed, while serum TSH levels increased slightly at 48 hours not related to the dose of administered T3S. No adverse events were reported.
In conclusion: 1) T3S is absorbed following oral administration in humans; 2) the oral administration of a single dose of T3S is converted to T3 in a dose-dependent manner and results in steady state serum T3 concentrations for 48 hours; 3) T3S may represent a new agent in combination with thyroxine in the therapy of hypothyroidism.
Disclosure: FS: Principal Investigator, Bracco S.p.A.. MG: Coinvestigator, Bracco S.p.A.. IR: Coinvestigator, Bracco S.p.A.. GS: Consultant, Bracco S.p.A.. DB: Employee, Bracco S.p.A.. GR: Employee, Bracco S.p.A.. PV: Coinvestigator, Bracco S.p.A.. Nothing to Disclose: GQ, LEB, AP
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters